Cover Image
市場調查報告書

缺血性腦中風:開發中產品分析

Ischemic Cerebral Stroke - Pipeline Review, H1 2015

出版商 Global Markets Direct 商品編碼 276005
出版日期 內容資訊 英文 37 Pages
訂單完成後即時交付
價格
Back to Top
缺血性腦中風:開發中產品分析 Ischemic Cerebral Stroke - Pipeline Review, H1 2015
出版日期: 2015年05月13日 內容資訊: 英文 37 Pages
簡介

缺血性腦中風是需要代謝的腦因血流量不足造成的症狀。由於腦部供氧量受限,造成腦缺氧,而引起腦組織壞死、腦梗塞、換言之就是缺血性腦中風。常見的症狀有視覺、身體行動、會話方面的功能障礙、失去意識、失明等。致病要素包含高血壓、糖尿病、抽煙、肥胖、血脂異常症等。

本報告提供缺血性腦中風治療藥的開發情形調查分析,提供開發中產品的概要,臨床實驗各階段產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關系統性資訊。

目錄

簡介

缺血性腦中風概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

治療藥的開發作的企業

  • Stempeutics Research Private Limited
  • Neurotec Pharma SL

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各類型分子

藥物簡介

  • Stempeucel-CS
  • NT-KC-005
  • BSc-2118
  • STEP Peptide Based Drug
  • Neuroprotective Therapy

開發中產品的最新趨勢

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6769IDB

Summary

Global Markets Direct's, 'Ischemic Cerebral Stroke - Pipeline Review, H1 2015', provides an overview of the Ischemic Cerebral Stroke's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ischemic Cerebral Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Cerebral Stroke and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Ischemic Cerebral Stroke
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Ischemic Cerebral Stroke and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Ischemic Cerebral Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Ischemic Cerebral Stroke pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Ischemic Cerebral Stroke
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Ischemic Cerebral Stroke pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Ischemic Cerebral Stroke Overview
  • Therapeutics Development
    • Pipeline Products for Ischemic Cerebral Stroke - Overview
    • Pipeline Products for Ischemic Cerebral Stroke - Comparative Analysis
  • Ischemic Cerebral Stroke - Therapeutics under Development by Companies
  • Ischemic Cerebral Stroke - Therapeutics under Investigation by Universities/Institutes
  • Ischemic Cerebral Stroke - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Ischemic Cerebral Stroke - Products under Development by Companies
  • Ischemic Cerebral Stroke - Products under Investigation by Universities/Institutes
  • Ischemic Cerebral Stroke - Companies Involved in Therapeutics Development
    • Neurotec Pharma SL
    • Stempeutics Research Private Limited
  • Ischemic Cerebral Stroke - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BSc-2118 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NTKC-005 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Peptide for Ischemic Cerebral Stroke - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Ischemic Cerebral Stroke - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stempeucel - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Ischemic Cerebral Stroke - Recent Pipeline Updates
  • Ischemic Cerebral Stroke - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Ischemic Cerebral Stroke, H1 2015
  • Number of Products under Development for Ischemic Cerebral Stroke - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Number of Products under Investigation by Universities/Institutes, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Comparative Analysis by Early Stage Development, H1 2015
  • Products under Development by Companies, H1 2015
  • Products under Investigation by Universities/Institutes, H1 2015
  • Ischemic Cerebral Stroke - Pipeline by Neurotec Pharma SL, H1 2015
  • Ischemic Cerebral Stroke - Pipeline by Stempeutics Research Private Limited, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Stage and Target, H1 2015
  • Number of Products by Stage and Mechanism of Action, H1 2015
  • Number of Products by Stage and Route of Administration, H1 2015
  • Number of Products by Stage and Molecule Type, H1 2015
  • Ischemic Cerebral Stroke Therapeutics - Recent Pipeline Updates, H1 2015
  • Ischemic Cerebral Stroke - Discontinued Products, H1 2015

List of Figures

  • Number of Products under Development for Ischemic Cerebral Stroke, H1 2015
  • Number of Products under Development for Ischemic Cerebral Stroke - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Comparative Analysis by Early Stage Products, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Top 10 Targets, H1 2015
  • Number of Products by Stage and Top 10 Targets, H1 2015
  • Number of Products by Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Top 10 Routes of Administration, H1 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2015
  • Number of Products by Top 10 Molecule Types, H1 2015
  • Number of Products by Stage and Top 10 Molecule Types, H1 2015
Back to Top